Cibus Q4 net loss rises 24% to USD 31.95 million on long-lived asset impairment of USD 9.12 million

Reuters

Mar 18

Cibus Q4 net loss rises 24% to USD 31.95 million on long-lived asset impairment of USD 9.12 million

Cibus published a press release reporting fourth-quarter financial results and a business update. Q4 revenue fell 13% to USD 1.06 million, while net loss widened 24% to USD 31.95 million. Q4 R&D expense decreased 24% to USD 9.39 million and SG&A expense fell 25% to USD 5.13 million, which the company attributed to cost reduction initiatives. Cash and cash equivalents were USD 9.92 million as of Dec. 31, and Cibus said it expects existing cash, including USD 19.8 million in net proceeds received in 2026 from a January public offering, to fund operating expenses and capital expenditures into late Q3 2026. Interim CEO Peter Beetham said the rice herbicide tolerance program remains on track for targeted initial commercial launches in Latin America in 2027 and the U.S. in 2028, and the company received its first customer payment from its Sustainable Ingredients program in Q4 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cibus Inc. published the original content used to generate this news brief on March 17, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2620408162"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620408162\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620408162?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 04:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620408162","market":"us","top_or_hot":-1,"title":"Cibus Q4 net loss rises 24% to USD 31.95 million on long-lived asset impairment of USD 9.12 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cibus Q4 net loss rises 24% to USD 31.95 million on long-lived asset impairment of USD 9.12 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cibus published a press release reporting fourth-quarter financial results and a business update. Q4 revenue fell 13% to USD 1.06 million, while net loss widened 24% to USD 31.95 million. Q4 R&amp;D expense decreased 24% to USD 9.39 million and SG&amp;A expense fell 25% to USD 5.13 million, which the company attributed to cost reduction initiatives. Cash and cash equivalents were USD 9.92 million as of Dec. 31, and Cibus said it expects existing cash, including USD 19.8 million in net proceeds received in 2026 from a January public offering, to fund operating expenses and capital expenditures into late Q3 2026. Interim CEO Peter Beetham said the rice herbicide tolerance program remains on track for targeted initial commercial launches in Latin America in 2027 and the U.S. in 2028, and the company received its first customer payment from its Sustainable Ingredients program in Q4 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cibus Inc. published the original content used to generate this news brief on March 17, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cibus Q4 net loss rises 24% to USD 31.95 million on long-lived asset impairment of USD 9.12 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCibus Q4 net loss rises 24% to USD 31.95 million on long-lived asset impairment of USD 9.12 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-18 04:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cibus Q4 net loss rises 24% to USD 31.95 million on long-lived asset impairment of USD 9.12 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cibus published a press release reporting fourth-quarter financial results and a business update. Q4 revenue fell 13% to USD 1.06 million, while net loss widened 24% to USD 31.95 million. Q4 R&amp;D expense decreased 24% to USD 9.39 million and SG&amp;A expense fell 25% to USD 5.13 million, which the company attributed to cost reduction initiatives. Cash and cash equivalents were USD 9.92 million as of Dec. 31, and Cibus said it expects existing cash, including USD 19.8 million in net proceeds received in 2026 from a January public offering, to fund operating expenses and capital expenditures into late Q3 2026. Interim CEO Peter Beetham said the rice herbicide tolerance program remains on track for targeted initial commercial launches in Latin America in 2027 and the U.S. in 2028, and the company received its first customer payment from its Sustainable Ingredients program in Q4 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cibus Inc. published the original content used to generate this news brief on March 17, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL1jQ7jx:1","article_id":"2620408162","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620408162","pubTimestamp":1773778350,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cibus published a press release reporting fourth-quarter financial results and a business update. Q4 revenue fell 13% to USD 1.06 million, while net loss widened 24% to USD 31.95 million. Q4 R&D expense decreased 24% to USD 9.39 million and SG&A expense fell 25% to USD 5.13 million, which the company attributed to cost reduction initiatives. Cash and cash equivalents were USD 9.92 million as of Dec. 31, and Cibus said it expects existing cash, including USD 19.8 million in net proceeds received in 2026 from a January public offering, to fund operating expenses and capital expenditures into late Q3 2026. Interim CEO Peter Beetham said the rice herbicide tolerance program remains on track for targeted initial commercial launches in Latin America in 2027 and the U.S. in 2028, and the company received its first customer payment from its Sustainable Ingredients program in Q4 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CBUS":"Cibus Inc"},"translate_title":"Cibus第四季度净亏损上升24%至3195万美元，长期资产减值为912万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CBUS":0.9},"content_text":"Cibus Q4 net loss rises 24% to USD 31.95 million on long-lived asset impairment of USD 9.12 million\n    \n\n        Cibus published a press release reporting fourth-quarter financial results and a business update. Q4 revenue fell 13% to USD 1.06 million, while net loss widened 24% to USD 31.95 million. Q4 R&D expense decreased 24% to USD 9.39 million and SG&A expense fell 25% to USD 5.13 million, which the company attributed to cost reduction initiatives. Cash and cash equivalents were USD 9.92 million as of Dec. 31, and Cibus said it expects existing cash, including USD 19.8 million in net proceeds received in 2026 from a January public offering, to fund operating expenses and capital expenditures into late Q3 2026. Interim CEO Peter Beetham said the rice herbicide tolerance program remains on track for targeted initial commercial launches in Latin America in 2027 and the U.S. in 2028, and the company received its first customer payment from its Sustainable Ingredients program in Q4 2025.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cibus Inc. published the original content used to generate this news brief on March 17, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}